Showing results 1 to 13 of 13
Title | Author(s) | Issue Date | Views | |
---|---|---|---|---|
2018 | 31 | |||
2013 | 64 | |||
2011 | 39 | |||
A phase II study of oxaliplatin, dose-intense capecitabine, and high-dose bevacizumab in the treatment of metastatic colorectal cancer Journal:Clinical Colorectal Cancer | 2011 | 49 | ||
2011 | 50 | |||
2016 | 30 | |||
2013 | 39 | |||
7-Mar-2014 | 60 | |||
Modulation of Circulating Protein Biomarkers in Cancer Patients Receiving Bevacizumab and the Anti-Endoglin Antibody, TRC105 Journal:Molecular Cancer Therapeutics | 2018 | 16 | ||
A phase I study of ABT-510 plus bevacizumab in advanced solid tumors Journal:Cancer Medicine | 2013 | 82 | ||
Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors Journal:Invest New Drugs | 2014 | 54 | ||
2014 | 49 | |||
Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: results from CALGB80303 (Alliance) Journal:Clinical Cancer Research | 2013 | 48 |